Understanding the CPA method
Biovator’s CPA Protein Test is performed in vitro to predict the allergenicity of new proteins targeted for introduction to humans, prior to use in drugs, food and cosmetics. Test read-outs measure released biomarkers from monocyte-like cells exposed to the proteins in which allergenicity is being tested. Protocols for the CPA Protein Test have been optimized by evaluating a comprehensive set of proteins with known allergenicity. These proteins include highly purified major allergens from foods, plants or house dust mites, and are compared to proteins with less or no allergenicity. In addition, many low-molecular substances associated with type IV hypersensitivity have been tested as controls. Proof of Concept has been documented and the test protocol will be validated in a multi-laboratory study during Q1-Q3 2010. The test components have been secured for a market presence.
The long-term goal with the CPA Protein Test is to replace today’s animal models and provide a validated test that is even more specific in the ability to predict risk for type I allergies toward new proteins proposed for human exposure. The market clearly needs a method that circumvents animal testing, yet offers sufficient precision in predicting the allergenic properties of newly introduced proteins, and such a solution would thus provide significant competitive advantages over current methods.
Biovator has the complete competence to technically support a variety of user needs